Galectin Therapeutics 3Q 2026: EPS ($0.04) — 10-Q Summary
Galectin Therapeutics (GALT) reported no revenue for Q3 2026, with a net loss of $3.57M, improved from $8.22M YoY. EPS loss narrowed to $0.04 from $0.13. R&D costs fell 40% due to reduced activity. The company has $11.7M in cash and expects funding through June 2027. It filed a Phase 3 protocol with the FDA and is exploring partnerships.
